Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Vaxneuvance by Quarter
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — International sales ($M) ($M)
Merck Vaxneuvance: $80M in Q2 2026, down 14.0% from a year earlier.
Latest, Q2 2026
80
Period ended Jun 30, 2026
Change on a year earlier
-14.0%
93 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
14
Documents cited below
Where the Q2 2026 figure comes from
“|| Vaxneuvance | 148 | 229 | -35 | 69 | 136 | -50 | 80 | 93 | -14”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Vaxneuvance ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vaxneuvance-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.